Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (81-90 of 172) with videos related to

Pageof 18
Sort By:
Gynecologic Oncology|January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study resultsDavid M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National SurveyEsmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
BMJ Open|January 2, 2020
Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinomaJohn R de Almeida, Christopher W Noel, Maria Veigas, et al.
Clinical and Translational Science|September 13, 2022
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog developmentNeeltje Steeghs, Aaron R Hansen, Glenn J Hanna, et al.
European Urology Oncology|September 10, 2020
Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell TumorGregory J Nason, Michael A S Jewett, Peter J Bostrom, et al.
Urology|February 1, 2020
Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the TestisGregory J Nason, Laura Donahoe, Marc de Perrot, et al.
Journal of Cancer Metastasis and Treatment|November 18, 2021
Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulatorsKimberly A Webster, Mary L O'Connor, Aaron R Hansen, et al.
BJU International|May 5, 2018
Gene expression signatures prognostic for relapse in stage I testicular germ cell tumoursJeremy Lewin, Laleh Soltan Ghoraie, Philippe L Bedard, et al.
Journal of Geriatric Oncology|March 14, 2023
Feasibility and acceptability of remote symptom monitoring (RSM) in older adults during treatment for metastatic prostate cancerGregory Feng, Milothy Parthipan, Henriette Breunis, et al.
Pageof 18

Showing results (81-90 of 172) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology|January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study resultsDavid M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National SurveyEsmail M Al-Ezzi, Amer Zahralliyali, Aaron R Hansen, et al.
BMJ Open|January 2, 2020
Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinomaJohn R de Almeida, Christopher W Noel, Maria Veigas, et al.
Clinical and Translational Science|September 13, 2022
Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog developmentNeeltje Steeghs, Aaron R Hansen, Glenn J Hanna, et al.
European Urology Oncology|September 10, 2020
Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell TumorGregory J Nason, Michael A S Jewett, Peter J Bostrom, et al.
Urology|February 1, 2020
Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the TestisGregory J Nason, Laura Donahoe, Marc de Perrot, et al.
Journal of Cancer Metastasis and Treatment|November 18, 2021
Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulatorsKimberly A Webster, Mary L O'Connor, Aaron R Hansen, et al.
BJU International|May 5, 2018
Gene expression signatures prognostic for relapse in stage I testicular germ cell tumoursJeremy Lewin, Laleh Soltan Ghoraie, Philippe L Bedard, et al.
Journal of Geriatric Oncology|March 14, 2023
Feasibility and acceptability of remote symptom monitoring (RSM) in older adults during treatment for metastatic prostate cancerGregory Feng, Milothy Parthipan, Henriette Breunis, et al.
Pageof 18